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The aim of this study was to determine the incidence of prostate cancer in patients with extramammary
Paget’s disease (EMPD). All cases of EMPD diagnosed between 1992 and 2007 in Shanghai Cancer
Hospital were collected and analyzed for the incidence of prostate cancer. The median follow-up was
78 months. In total, 10 cases of invasive and 38 cases of in situ EMPD had been registered. A second
malignancy was found in 30% (3⁄10) of patients with invasive EMPD and in 28.9% (11⁄38) of patients
with in situ EMPD. [Corrections added after online publication, 19 July 2010: data for total number of
cases of invasive and in situ EMPD registered, and for second malignancy in patients with invasive
EMPD and in situ EMPD amended after authors re-checked the PAGETS disease database.] Patients
had an increased risk of developing a second cancer compared with the general population (standard-
ized incidence ratio: 1.7; 95% conﬁdence interval 1.2–2.4). Sixteen patients had serum prostate-speciﬁc
antigen (PSA) level above 4 ng⁄mL; ﬁve developed prostate cancer, three of them with PSA levels
beyond 100 ng⁄mL. The incidence of prostate cancer is 10.4% in this patient group. Patients with
EMPD were more likely to have prostate cancer than the general population. Although the prognosis of
EMPD is fairly good, a thorough search for a second tumor is recommended.
Key words: PSA; prostate cancer; EMPD disease.
Ding-Wei Ye, Department of Urology, Cancer Hospital, Fudan University, No. 270 Dong’an Road,
Shanghai 200032, China. e-mail: dwye@shca.org.cn
Paget disease (PD) was ﬁrst described by Sir
James Paget in 1874 (1), referring to a malignant
entity involving the nipple of the breast. He also
found that this clinical entity could involve other
organs.In1889,Crockerdescribedlesionsonthe
scrotum and penis that exhibited similar histo-
logic features to mammary PD (mPD) and
deﬁnedasextramammaryPagetdisease(EMPD)
(2). Although it is a rare disease, EMPD is a
marker for defects in the body’s cancer surveil-
lancemechanismsandearlydetectionofasecond
tumor could be lifesaving (3). However, there are
little epidemiology data about the incidence of
EMPD and its relationship to a visceral carci-
noma. Moreover, no clear guidelines have been
established for the diagnosis, treatment and fol-
low-upofpatientswithEMPD.
In our clinical practice, we have found
increased prostate-speciﬁc antigen (PSA) levels
in patients with EMPD, leading to the investiga-
tion of prostate cancer. The aim of this popula-
tion-based study was to evaluate the incidence
of prostate cancer in patients with EMPD.
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777PATIENTS AND METHODS
All cases of EMPD diagnosed from 1992 to 2007
were included in the study. The follow-up of EMPD
was completed by December 1, 2009. All instances
of EMPD in this study were histologically con-
ﬁrmed.
A total of 48 male patients with EMPD were regis-
tered at the Shanghai Cancer Hospital. A thorough
physical examination and diagnostic tests, including
serum tumor markers, cystoscopy, colonoscopy and
chest⁄abdominal⁄pelvic computed tomography (CT)
scan were used to exclude the presence of an internal
noncutaneous malignancy. As EMPD may present as
adenocarcinoma of a skin appendage, pathologic
reviews were also performed in those patients.
The time between the diagnosis of EMPD and the
second tumor, adjusted for age and calendar year of
the EMPD diagnosis, was taken into account. The
incidence of the second tumor (observed) was com-
pared with the incidence of the same primary cancer
in the general population (expected). The 95% conﬁ-
dence intervals were calculated using the Poisson
probability. Values of p < 0.05 were considered sta-
tistically signiﬁcant. Serum total PSA was measured
by the method of time-resolved ﬂuoroimmunoassay.
RESULTS
Epidemiology
The mean age at diagnosis was 68 years (range
36–79 years, n = 48). Thirty-eight cancers
were localized in the penoscrotal region; two
on the extragenital skin, including one on the
skin of the trunk and one in the groin; three on
the axilla; and ﬁve in the perianal area
(Table 1).
A second malignancy was found in 30% (3⁄10)
of patients with invasive EMPD and 28.9%
(11⁄38) of patients with in situ EMPD. [Correc-
tions added after online publication, 19 July
2010: data for second malignancy in patients
with invasive EMPD and patients with in situ
EMPD amended after authors re-checked the
PAGETS disease database.] Patients had an
increased risk of developing a second cancer
compared with the general population (stan-
dardized incidence ratio: 1.7; 95% conﬁdence
interval1.2–2.4).Themostfrequentlocalizations
of these cancers were the colorectum, the pros-
tate, the breast and the extragenital skin (data
notshown).
Serum PSA level and incidence of prostate cancer in
patients with EMPD
A total of 16 patients showed a PSA level above
4n g⁄mL and this incidence of increase is
33.33% (16⁄48) vs 6.7% in the general popula-
tion (4), among whom ﬁve had prostate cancer,
as established by transrectal ultrasound biopsy
(Table 2). The incidence of prostate cancer in
this patient group is 10.4% (5⁄48), which is
much higher than the incidence in the general
population (4). The detailed clinicopathologic
characteristics of the ﬁve patients are listed in
Table 3.
DISCUSSION
In this study, we found that EMPD patients had
an increased risk of developing a second cancer
and that patients with increased PSA levels had
a higher incidence of prostate cancer. We there-
fore suggest a thorough search for a second
tumor in EMPD patients.
The location of the underlying internal malig-
nancy is linked to the location of the EMPD.
Speciﬁcally, a perianal location may signify a
malignancy of the gastrointestinal tract, while a
penile, scrotal or groin location may be associ-
ated with an adenocarcinoma of the
Table 1. Clinicopathologic features of the patients with EMPD
In situ EMPD Invasive EMPD p-value
No. of patients 38 10
Age (years) 71 (48–79) 61 (36–76) 0.067
Longest diameter of the skin lesion (cm) 6 (1–20) 6.5 (5–18) 0.001
Prostate cancer 1 4 0.03
Time to prostate cancer (years) 3 6.8 (3–11)
Data are presented as median (range). EMPD, extramammary Paget’s disease.
[Corrections added after online publication, 19 July 2010: mistakes in table amended after authors re-checked the
PAGETS disease database.]
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ciated carcinomas in 31% of their patients
while Pierie et al. (6) found concurrent second-
ary malignancies in 42% of their patients. Iwe-
nofu et al. (7) found that the median age of
their patients was 68 years, while Pierie et al.
(6) found a median age of 70 years. Taking the
patient age in the present study into account,
patients with EMPD had 1.7 times higher risk
of developing a second cancer during a follow-
up period of 15 years. Chandra’s hypothesis
that EMPD is a marker for deﬁcits in the
body’s cancer surveillance mechanism (3) could
be supported by our study. About one-third of
the tumor recurrences were adenocarcinomas,
mostly originating from the colorectum, pros-
tate and breast.
In this study, there are no concurrent pri-
mary malignancies or prior primary malig-
nancies occurring during the follow-up period.
Although we thoroughly searched for a recur-
rence of cancer after EMPD, new tumors could
develop in the future. Therefore, the number of
other cancers before and after EMPD could
both be underestimated. The large number of
other cancers in patients with in situ and inva-
sive EMPD in this study supports the recom-
mendation for a thorough search for other
malignancies.
Overall, the prognosis for EMPD was fairly
good. No treatment modalities or other tumors
before or after EMPD tended to be associated
with a higher risk of death. This ﬁnding was
signiﬁcant in univariate analyses, and thus with-
out adjustment for age and sex. After adjusting
for all variables, patients with no treatment had
an elevated risk of death. Thus, the recom-
mended diagnostic tests were a digital rectum
examination (DRE), colonoscopy, CT of the
abdomen and pelvis, and PSA testing in patients
with penoscrotal EMPD. This increased risk
may be caused by the fact that these patients
had more comorbidities. The results of this
survival analysis should be considered within
the limitations of the small number of patients
and probable underestimation of the number of
other tumors.
In this study, ﬁve patients developed prostate
cancer. If there is any communication between
the prostatic duct system and the surface
epidermis, the cancer could spread from the
skin site to the scrotal skin. The likeliest route
is via prostatic ducts traversing urethral epithe-
lium. There is histologic proof that prostate
cancer presenting as epidermal involvement
originated from EMPD (8), just like Paget’s
disease of the breast, the chemotaxis of these
breast cancer cells, which eventually migrate
into the overlying nipple epidermis (9). How-
ever, this theory remains unproven as there
was no laboratory evidence of non-involve-
ment of the scrotal area and nonlesional sites
were not biopsied. It may be of interest to
observe any change in surface skin involve-
ment during follow-up of our patients.
Another possibility is that PD of the nipple is
a stem cell disease (10), meaning that EMPD
may be a result of proliferation in the stem cell
compartment.
Table 2. Characteristics of PSA in 48 EMPD patients
PSA level (ng⁄mL) Below 4 Above 4
Prostate cancer (N) 0 5
No prostate cancer (N) 32 11
Sum (N) 32 16
EMPD, extramammary Paget’s disease.
Table 3. Clinicopathologic data of ﬁve EMPD patients with prostate cancer
Case Age
(years)
Longest
diameter
of the skin
lesion (cm)
Invasion Serum
PSA
level
(ng⁄mL)
CEA
(lg⁄L) Gleason
score
(biopsy)
Time to
prostate
cancer
(years)
Outcome Follow-up
(months)
1 70 11 Subcutaneous tissue 166 52.4 3 + 3 6 RP 12
2 61 12 Subcutaneous tissue 101 1.2 3 + 3 11 RP 150
3 60 10 Subcutaneous tissue 89 20 3 + 4 3 ADT 60
4 65 7 Epidermis
1 120 16 4 + 3 3 ADT 60
5 75 13 Subcutaneous tissue 38 22 4 + 3 8 ADT 120
EMPD, extramammary Paget’s disease; PSA, prostate-speciﬁc antigen; CEA, carcinoembryonic antigen; RP
radical prostatectomy; ADT, androgen deprivation therapy.
[Corrections added after online publication, 19 July 2010: Footnote referring to Age (column 2) removed;
1‘Dermis’ amended to ‘Epidermis’.]
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and most of the reports are from single
centers, especially in Asians. The disease may
also be diﬀerent in patients with a diﬀerent
ethnical background. In other words, it may
be of interest to investigate the mechanism of
EMPD through a multi-center cooperative
study.
PSA positivity can be seen in cases of EMPD
without associated adenocarcinoma of the pros-
tate (11). The incidence of prostate cancer of
EMPD patients is 10.4% (5⁄48) compared to
9.2% in the general population (4). Until now,
no clear correlation between prostate cancer
and EMPD has been demonstrated. There are
also reports that immunohistochemical investi-
gations of the tumor specimens from the pros-
tate revealed an immunoproﬁle, which was very
diﬀerent from that of the primary skin lesion,
and no case of EMPD with PSA positivity
seems to represent an extension of an underlying
prostatic adenocarcinoma (11). It is known that
prostate cancer can be found in at least 1⁄3o f
men in their 80s (12). The number of other
tumors in this study was too small to determine
the risk of developing a second tumor at a spe-
ciﬁc localization by means of a person-years
analysis.
In 2004, the WHO noted that total serum
PSA is still the best marker for the detection of
prostate cancer, and the threshold PSA value
for undergoing a biopsy was set at 4 ng⁄mL
(13). Increased PSA levels were observed in
33% of the male EMPD patients[16⁄48] com-
pared with 6.7% in the general population. We
do not currently have an explanation for this
ﬁnding.
The incidence of prostate cancer in EMPD
patients whose serum total PSA was above
4.0 ng⁄mL is 31.25% (5⁄16). In the general pop-
ulation, for those with PSA levels above
4.0 ng⁄mL, prostate cancer is determined by
biopsy in 25–30% of men evaluated (14).
EMPD patient had a higher incidence of pros-
tate cancer with PSA levels above 4.0 ng⁄mL,
and interestingly, PSA levels are usually higher
than 90 ng⁄mL in EMPD prostate cancer
patients (80%, 4⁄5). However, further investiga-
tion is required.
Results from other studies have conﬁrmed the
prognostic value of the depth of skin invasion of
EMPD (15). Our data did not show a diﬀerence
in age between invasive and in situ EMPD, and
prostate cancer incidence was also independent
of EMPD type (invasive, in situ).
CONCLUSIONS
The prognosis for patients with EMPD is fairly
good, but a thorough examination for other
tumors is recommended in addition to regular
check-ups for at least 5 years, especially for
patients with increased PSA levels. For EMPD
on the male genital skin, the most likely sites of
other tumors are the colorectum and prostate.
Therefore, PSA and DRE are recommended for
these patients.
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